2:34 PM
Apr 19, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eiger raises $49.5M following Phase II HDV readout for Lambda

Eiger reported data from the Phase II LIMT HDV trial showing that high-dose Lambda as monotherapy led to a 36% durable virologic response rate at 24 weeks following treatment among 14 evaluable patients with chronic hepatitis D virus infection. The company...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >